Clinical Trial Update: Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma [Phase 3]

View source ↗

Summary

This Phase 3 trial investigates nivolumab or brentuximab vedotin in combination with chemotherapy for newly diagnosed stage III-IV classical Hodgkin lymphoma; r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Classical Hodgkin Lymphoma

Drugs mentioned

• Brentuximab vedotin (Brentuximab vedotin)
• nivolumab (nivolumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-06-12